Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)

Luca Lanino, Matteo Zampini, Ivan Civettini, Daniele Ramazzotti, Alessia Campagna, Elena Riva, Denise Ventura, Nicole Pinocchio, Pasquale Niscola, Marco Gabriele Raddi, Angela Consagra, Federica Pilo, Antonella Poloni, Mariarita Sciumè, Andrea Patriarca, Stefania Paolini, Carlo Finelli, Andrea Castelli, Pellegrino Musto, Anna Calvisi, Grazia Sanpaolo, Monia Marchetti, Elisa Diral, Germana Beltrami, Carmen Fava, Claudio Fozza, Chiara Frairia, Carmine Selleri, Daniela Barraco, Domenico Pastore, Rosanna Ciancia, Elena Crisa, Enrico Balleari, Susanna Gallo, Vincenzo Pavone, Esther Natalie Oliva, Giulia Maggioni, Ferdinando Frigeri, Gabriele Todisco, Antonio Russo, Alessandro Buizza, Ivan Ferrari, Giulia Figini, Alessandra Crespi, Elisa Calvetti, Chiara Milanesi, Nicla Manes, Francesco Pesce, Saverio D'Amico, Gianluca Asti, Elisabetta Sauta, Guido Sanguinetti, Gastone Castellani, Marilena Bicchieri, Ilaria Naldi, Francesca Ficara, Valeria Santini, Marta Ubezio, Matteo Della Porta

Blood (2025) 146 (Supplement 1): 3842.

https://doi.org/10.1182/blood-2025-3842

Published: 2025

Journal Articles

Thrombocytopenia at diagnosis adversely affects overall and leukemia-free survival in lower-risk MDS patients: A retrospective study from the FISiM registry

Anna Calvisi, Rosangela Filiberti, Daniela Barraco, Massimo Bernardi, Isabella Capodanno, Andrea Castelli, Rosanna Ciancia, Carmen Fava, Carla Fili, Chiara Frairia, Francesco Frattini, Piero Galieni, Pasquale Niscola, Stefania Paolini, Andrea Patriarca, Anna Maria Pelizzari, Grazia Sanpaolo, Carmine Selleri, Francesco Alesiani, Gianni Binotto, Costanza Bosi, Catello Califano, Barbara Castagnari, Elena Crisa, Monica Crugnola, Marco De Gobbi, Matteo Della Porta, Nicola Di Renzo, Dario Ferrero, Carlo Finelli, Carla Foli, Claudio Fozza, Maurizio Frezzato, Ferdinando Frigeri, Gianluca Guaragna, Monia Marchetti, Daniele G. Mattei, Mara Memoli, Paola Minetto, Alfredo Molteni, Pellegrino Musto, Esther Natalie Oliva, Giuseppe Alberto Palumbo, Fabrizio Pane, Giuseppe Pietrantuono, Federica Pilo, Antonella Poloni, Giulia Rivoli, Mariarita Sciumè, Rodolfo Tassara, Mauro Turrini, Letizia Zannoni, Ilaria Naldi, Enrico Balleari, Valeria Santini, Francesco Onida

Blood (2025) 146 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2025-2080

Published: 2025

Journal Articles

Occurrence of immune-mediated inflammatory disorders (IMIDs) during the course of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) negatively impacts overall survival (OS): A cohort-based study

Jose Torregrosa, Thomas Brunet, Lin-Pierre Zhao, Pierre Fenaux, Arsene Mekinian, Maria Julia Montoro, David Valcarcel, Sophie Dimicoli-Salazar, Estibaliz Lazarro, Claudio Fozza, Yohann Foucher

Blood (2025) 146 (Supplement 1): 2076.

https://doi.org/10.1182/blood-2025-2076

Published: 2025

Journal Articles

The prognostic value for survival of frailty and patient-reported outcomes in relapsed/refractory multiple myeloma: Results from a prospective multicenter observational study

Fabio Efficace, Gianluca Gaidano, Pasquale Niscola, Serena Puglia, Francesco Sparano, Katia Codeluppi, Elisabetta Antonioli, Catello Califano, Lajos Floro, Ombretta Annibali, Claudio Fozza, Agostino Tafuri, Patrizio Mazza, Leonardo Potenza, Marco Vignetti, Michele Cavo, Maria Teresa Petrucci

Blood (2025) 146 (Supplement 1): 138.

https://doi.org/10.1182/blood-2025-138

Published: 2025

Journal Articles

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Blood (2024) 144 (Supplement 1): 3155.

https://doi.org/10.1182/blood-2024-207877

Published: 2024

Journal Articles

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Blood (2024) 144 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2024-210768

Published: 2024

Journal Articles

The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema

Blood (2024) 144 (Supplement 1): 404.

https://doi.org/10.1182/blood-2024-204633

Published: 2024

Journal Articles

Pomalidomide-Based Regimens with Monoclonal Antibodies As Salvage Therapy for Patients with Multiple Myeloma: Sardinian, Multicenter, Retrospective Clinical Practice Experience with 54 Cases Outside of Controlled Clinical Trials

Daniele Derudas, Luigi Podda, Andrea Murtas, Luca Deiana, Cristina Depau, Annamaria Liguori, Claudio Fozza, Giorgio La Nasa, Angelo D. Palmas

Blood (2024) 144 (Supplement 1): 7844.

https://doi.org/10.1182/blood-2024-208749

Published: 2024

Journal Articles

Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Blood (2024) 144 (Supplement 1): 4535.

https://doi.org/10.1182/blood-2024-202477

Published: 2024

Journal Articles

FATE and Role of Peripheral Blood CD26+ Leukemia STEM CELLS at Diagnosis in Chronic Myeloid Leukemia Patients: FINAL Results of Prospective Flowers Study

Blood (2024) 144 (Supplement 1): 995.

https://doi.org/10.1182/blood-2024-204689

Published: 2024

Journal Articles

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Blood (2023) 142 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2023-178505

Published: 2023

Journal Articles

Health-Related Quality of Life and Symptom Burden Profile of Patients with Pre-Fibrotic and Overt Myelofibrosis: A Preliminary Report from the Gimema-Prophecy Observational Study

Blood (2023) 142 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2023-186429

Published: 2023

Journal Articles

Isatuximab-Based Regimens As Salvage Therapy for Patients with Multiple Myeloma: Sardinian, Multicenter, Retrospective Clinical Practice Experience with 27 Cases Outside of Controlled Clinical Trials

Daniele Derudas, Luigi Podda, Angelo D. Palmas, Rita Floris, Annamaria Liguori, Cristina Depau, Alessandro Bianchi, Claudio Fozza, Giorgio La Nasa

Blood (2023) 142 (Supplement 1): 6658.

https://doi.org/10.1182/blood-2023-190412

Published: 2023

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an Italian Prospective Study from the CML Campus

Blood (2023) 142 (Supplement 1): 6363.

https://doi.org/10.1182/blood-2023-188523

Published: 2023

Journal Articles

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2023-188305

Published: 2023

Journal Articles

Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform

Blood (2023) 142 (Supplement 1): 3714.

https://doi.org/10.1182/blood-2023-180574

Published: 2023

Journal Articles

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Blood (2023) 142 (Supplement 1): 3168.

https://doi.org/10.1182/blood-2023-182981

Published: 2023

Journal Articles

Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study

Blood (2022) 140 (Supplement 1): 8119–8121.

https://doi.org/10.1182/blood-2022-166039

Published: 2022

Journal Articles

Acute Myeloid Leukemia (AML) Risk Stratification Using the European Leukemianet 2022 Classification in a Real-Life Cohort of Patients from Sardinia, Italy

Giovanna Piras, Antonella Uras, Antonella Cucca, Maria Monne, Alessandro Costa, Sabrina Chiriu, Francesco Longu, Marco Murineddu, Luigi Benedetto Arru, Alessandro Bianchi, Anna Calvisi, Alessandra Di Francesco, Alessandro Murgia, Francesca Cambosu, Mauro P Flagiello, Maria Antonia Isoni, Giovanni Caocci, Claudio Fozza, Angelo D. Palmas

Blood (2022) 140 (Supplement 1): 9156–9157.

https://doi.org/10.1182/blood-2022-163249

Published: 2022

Journal Articles

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Luca Lanino, Prassede Salutari, Alessandra Perego, Bruno Fattizzo, Marta Riva, Marta Ubezio, Pellegrino Musto, Daniela Cilloni, Esther Natalie Oliva, Maria Teresa Voso, Anna Maria Pelizzari, Antonella Poloni, Isabella Capodanno, Chiara Elena, Claudio Fozza, Fabrizio Pane, Massimo Breccia, Marco De Gobbi, Francesco Di Bassiano, Daniela Barraco, Elena Crisà, Dario Ferrero, Chiara Frairia, Antonella Vaccarino, Davide Griguolo, Stefania Paolini, Martina Quintini, Mariarosaria Sessa, Mauro Turrini, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Cristina Foli, Alfredo Molteni, Ubaldo Occhini, Giulia Rivoli, Carmine Selleri, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Alessandro Rambaldi, Ilaria Tanasi, Patrizia Tosi, Ilaria Naldi, Valeria Santini, Matteo G. Della Porta

Blood (2022) 140 (Supplement 1): 6945–6948.

https://doi.org/10.1182/blood-2022-164559

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)

Thrombocytopenia at diagnosis adversely affects overall and leukemia-free survival in lower-risk MDS patients: A retrospective study from the FISiM registry

Occurrence of immune-mediated inflammatory disorders (IMIDs) during the course of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) negatively impacts overall survival (OS): A cohort-based study

The prognostic value for survival of frailty and patient-reported outcomes in relapsed/refractory multiple myeloma: Results from a prospective multicenter observational study

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema

Pomalidomide-Based Regimens with Monoclonal Antibodies As Salvage Therapy for Patients with Multiple Myeloma: Sardinian, Multicenter, Retrospective Clinical Practice Experience with 54 Cases Outside of Controlled Clinical Trials

Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

FATE and Role of Peripheral Blood CD26+ Leukemia STEM CELLS at Diagnosis in Chronic Myeloid Leukemia Patients: FINAL Results of Prospective Flowers Study

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Health-Related Quality of Life and Symptom Burden Profile of Patients with Pre-Fibrotic and Overt Myelofibrosis: A Preliminary Report from the Gimema-Prophecy Observational Study

Isatuximab-Based Regimens As Salvage Therapy for Patients with Multiple Myeloma: Sardinian, Multicenter, Retrospective Clinical Practice Experience with 27 Cases Outside of Controlled Clinical Trials

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an Italian Prospective Study from the CML Campus

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study

Acute Myeloid Leukemia (AML) Risk Stratification Using the European Leukemianet 2022 Classification in a Real-Life Cohort of Patients from Sardinia, Italy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only